Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy

Abstract Background In situ tumor vaccine has been gradually becoming a hot research field for its advantage of achieving personalized tumor therapy without prior antigen identification. Various in situ tumor vaccine regimens have been reported to exert considerable antitumor efficacy in preclinical...

Description complète

Détails bibliographiques

Auteurs principaux:	Zhichen Sun, Yanhong Chu, Jie Xiao, Yueling Yang, Fanyan Meng, Xinyue Wang, Yanbing Dong, Junmeng Zhu, Yirong Wu, Lanqun Qin, Yaohua Ke, Baorui Liu, Qin Liu
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2023-09-01
Collection:	Journal of Translational Medicine
Sujets:	TLR9 agonist OX40 agonist Radiation In situ vaccine Tumor microenvironment
Accès en ligne:	https://doi.org/10.1186/s12967-023-04504-w
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!